Consistent with the findings that ERBB3 promotes hematogenous metastasis of ovarian cancer, depletion of ERBB3 by siRNA or treatment with ERBB3-specific monoclonal antibodies reduced the formation of CTCs and the incidence of hematogenous metastasis of ovarian cancer in mouse models [7]. Here, ERBB3 is linked to ovarian carcinoma.